Companion Animal Rare Disease Variant Modeling Service

BioVenic supports canine and feline rare disease research by linking candidate variant analysis to species-relevant experimental models. Our flexible workflows cover variant prioritization, cell or animal model strategy, gene-expression assessment, pathway interpretation, and measurable phenotype endpoints for functional research.

Functional genomics / companion animal disease

From a Rare Canine or Feline Variant to a Testable Disease Mechanism

Sequencing studies can identify plausible variants in dogs and cats, yet rarity, predicted damage, or human-gene annotation alone does not establish causality. Interpretation also depends on inheritance, family segregation, tissue expression, phenotype concordance, and the possibility of linked or complex variants.

BioVenic helps animal genetics and comparative genomics teams move from sequence findings to a staged validation plan. We align the hypothesis with suitable models, controls, and decision criteria.

Research services

Companion Animal Rare Disease Variant Modeling: Core Service Scope

Commission work packages individually or as a staged program, tailored to available samples, disease biology, and genetic evidence.

Discovery & triage

Candidate Variant Prioritization and Segregation Review

Review WGS/WES candidate lists, genotype quality, reference-build mapping, pedigree consistency, allele frequency, and orthology. Distinguish coding, splice, regulatory, and structural candidates without overstating predictions.

Output: a ranked variant dossier with evidence gaps and recommended confirmations.

Model selection

Species-Relevant Cell and Animal Model Strategy

Evaluate primary, established, or isogenic edited cells and animal-model routes for tissue relevance, feasibility, and welfare. Select knockout, knock-in, rescue, or expression comparisons according to the mechanism.

Output: a model decision brief, controls, risks, and phased feasibility plan.

Molecular validation

Gene Expression, Splicing, and Allelic Effects

Plan RT-qPCR, RNA sequencing, splice-junction, or allele-specific expression studies when feasible. Combine transcript results with protein localization, abundance, or activity to assess functional consequences.

Output: comparative expression or splice readouts with interpretation and limitations.

Functional evidence

Variant Perturbation, Rescue, and Phenotype Assays

Design reference-versus-variant comparisons, perturbation, rescue, and functional phenotyping. Assess protein activity, metabolites, pathways, cell morphology, or biomarkers with controls for background effects.

Output: an experimental evidence package indicating supported and unresolved mechanisms.

Pathway Analysis and Translational Interpretation

Integrate phenotype, transcriptomic results, protein function, and ortholog evidence; distinguish variant effects from general stress and limit unsupported clinical extrapolation.

Deliverable: pathway map, prioritized endpoints, and follow-up study recommendations.

Match the Variant Mechanism to the Right Validation Assay

Match research models and assays to the hypothesis, not a fixed generic test panel.

Variant hypothesis Potential research model Informative readout Key interpretation limit
Coding loss of function Isogenic edited cells or matched disease-derived cells Protein abundance, catalytic activity, rescue response Compensation and gene dosage can obscure effects.
Missense alteration Reference/variant expression with relevant controls Localization, stability, substrate or pathway function Overexpression may misrepresent native expression.
Splice-region change Relevant tissue RNA; minigene only if necessary Exon usage, junction sequencing, isoform balance Splicing may differ between cell types or species.
Regulatory or structural variant Allelic expression or genomic-context model Transcript dosage, breakpoint checks, pathway endpoints Linked variants and chromatin context may confound attribution.

Decision principle: a variant supported by segregation and predictions may remain a candidate until independent functional, molecular, or disease-mechanism evidence is obtained.

Stage-gated execution

Rare Disease Variant Modeling Workflow

The program uses feasibility checkpoints to refine the model and stop weak candidates early.

Useful starting materials

Variant calls or VCFs, reference genome build, pedigree and phenotypes, sample metadata, prior assay results, available cell/tissue materials, and the target research decision.

01 / Frame

Define the Phenotype

Agree on disease classification, inheritance assumptions, affected tissues, and the central causal question.

02 / Prioritize

Audit Variant Evidence

Review genotype quality, segregation, allele frequency, orthology, and plausible competing variants.

03 / Select

Choose the Model

Match cell background, variant mechanism, tissue expression, control groups, and ethical feasibility.

04 / Measure

Establish Readout Quality

Set quantitative endpoints, reference controls, replication strategy, and predefined acceptance criteria.

05 / Validate

Test Variant Effects

Compare alleles or perturbations and assess whether rescue or orthogonal assays strengthen the evidence.

06 / Decide

Integrate and Report

Summarize phenotype concordance, effect sizes, limitations, and the most informative next experiment.

Research Deliverables for Variant-to-Function Studies

Deliver evidence for a research decision, not only variant lists or assay signals.

Scope and delivery format are specified per project.

Evidence & Feasibility

Prioritized candidate table, inheritance assessment, model recommendation, controls, QC checkpoints, and study design assumptions.

Experimental Results

Agreed expression, splicing, protein-function, cell-phenotype, or pathway data with replicate-level documentation.

Scientific Interpretation

Integrated evidence summary, alternative explanations, validation confidence, unresolved questions, and next-step recommendations.

Have a Canine or Feline Rare Disease Variant to Investigate?

Share the candidate gene, disease phenotype, and available data to discuss a staged validation plan.

Published Data on Canine Rare Disease Variant and Phenotype Validation

In a published investigation of a Doberman Pinscher with progressive neurodegeneration, researchers identified a homozygous MAN2B1 missense variant and evaluated disease-associated phenotypes. The figure shows hematoxylin-and-eosin-stained cerebral cortex sections with extensive intracellular vacuolar inclusions. These pathology findings provided a tissue-level endpoint alongside the study's genome analysis and biochemical evidence of absent detectable α-mannosidase activity.1

The study illustrates why a candidate variant is more informative when genomic evidence is interpreted together with relevant functional and phenotypic observations. For companion animal rare disease projects, BioVenic can help plan the sequence of variant review, species-matched model selection, expression or protein assays, and interpretable phenotype measurements. The published results are independent research, not data generated by BioVenic.1

Hematoxylin-and-eosin microscopy of the canine cerebral cortex showing intracellular vacuolar pathology in an inherited lysosomal disease. (OA Literature)
Fig.1 Cerebral cortex sections from a canine α-mannosidosis case showing abundant intracellular vacuolar inclusions. 1,3

Why Choose BioVenic for Rare Disease Variant Modeling

A research plan that integrates genetic evidence with model feasibility and interpretable functional readouts.

Species-Aware Design

Align canine or feline biology with sample availability and tissue-specific readouts.

Evidence-Guided Priorities

Identify the most useful next experiment before expanding model complexity.

Modular Validation

Combine genetic, molecular, and functional methods according to project feasibility.

Decision-Ready Reports

Document findings, controls, uncertainty, and recommendations for subsequent studies.

Frequently Asked Questions About Companion Animal Variant Validation

Yes. Projects can start with a candidate gene or a shortlist from WGS, WES, or pedigree studies. The first stage assesses genotype quality, segregation, predicted mechanism, and model feasibility before functional studies are proposed.

References

  1. Bullock, Garrett, et al. "A Homozygous MAN2B1 Missense Mutation in a Doberman Pinscher Dog with Neurodegeneration, Cytoplasmic Vacuoles, Autofluorescent Storage Granules, and an α-Mannosidase Deficiency." Genes 14.9 (2023): 1746. https://doi.org/10.3390/genes14091746.
  2. Esders, Stella L., et al. "Single Nucleotide Polymorphisms Associated with AA-Amyloidosis in Siamese and Oriental Shorthair Cats." Genes 14.12 (2023): 2126. https://doi.org/10.3390/genes14122126.
  3. Distributed under Open Access license CC BY 4.0, without modification.
Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inquiry Basket